Matthew Zibelman
Assistant Professor
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (5)
Supplementary TablesSupplementary Table 1: Patient and tumor sample informationSupplementary Table 2: Tumor mutation burdenSupplementary Table 3: Unfiltered whole exome sequencing mutation analysisSupplementary Table 4: Filtered whole exome sequencing mutation analysisSupplementary Table 5: Immunohistochemistry scores of tumorsSupplementary Table 6: FACS panel for PBMC analysisSupplementary Table 7: Geometric mean fluorescence intensity (GMFI) from PBMC FACSSupplementary Table 8: Representativeness of Study Participants
Year:
2025
Background Immune checkpoint inhibitors (ICIs) have transformed the oncology treatment landscape. Despite substantial improvements for some patients, the majority do not benefit from ICIs, indicating a need for predictive biomarkers to better inform treatment decisions. Methods A de-identified pan-cancer cohort from the Tempus multimodal real-world database was used for the development and validation of the Immune Profile Score (IPS) algorithm leveraging Tempus xT (648 gene DNA panel) and xR (RNAseq). The cohort consisted of advanced stage cancer patients treated with any ICI-containing regimen as the first or second line of therapy. The IPS model was developed utilizing a machine learning framework that includes tumor mutational burden (TMB) and 11 RNA-based biomarkers as features. Results IPS-High patients demonstrated significantly longer overall survival (OS) compared to IPS-Low patients (HR=0.45, 90% CI [0.40-0.52]). IPS was consistently prognostic in PD-L1 (positive/negative), TMB (High/Low), microsatellite status (MSS/MSI-H), and regimen (ICI only/ICI + other) subgroups. Additionally, IPS remained significant in multivariable models controlling for TMB, MSI, and PD-L1, with IPS HRs of 0.49 [0.42-0.56], 0.47 [0.41-0.53], and 0.45 [0.38-0.53] respectively. In an exploratory predictive utility analysis of the subset of patients (n=345) receiving first-line (1L) chemotherapy (CT) and second-line (2L) ICI, there was no significant effect of IPS for time to next treatment on CT in L1 (HR=1.06 [0.85-1.33]). However, there was a significant effect of IPS for OS on ICI in L2 (HR=0.63 [0.46-0.86]). A test of interaction was statistically significant (p<0.01). Conclusions Our results demonstrate that IPS is a generalizable multi-omic biomarker that can be widely utilized clinically as a prognosticator of ICI based regimens. Graphical Abstract Key Messages What is already known on this topic – Advancements of multi-omic profiling technology in research settings has demonstrated the potential value of novel immune biomarkers for forecasting response to ICI therapies. However, despite these advances there remains an unmet clinical need for implementation of more sensitive and generalizable biomarkers to better predict patient outcomes to ICI due to limited availability of clinical multi-omic testing and validation cohorts. What this study adds – Our results demonstrate that IPS is a generalizable multi-omic biomarker that can be widely utilized clinically as a prognosticator of ICI based regimens. Importantly, IPS-High may identify patients within subgroups (TMB-L, MSS, PD-L1 negative) who benefit from ICI beyond what is predicted by existing biomarkers. How this study might affect research, practice or policy – In the near term IPS results can support patient stratification across pan-solid tumor cohorts to help inform clinicians and researchers which patients are more likely to benefit from ICI based regimens. In the future IPS may support label expansion of ICIs into cancer types without current approvals, and also potentially improve patient selection to minimize over-treatment with ICI in patients unlikely to respond.
Year:
2024
Purpose: Based on preclinical evidence of epigenetic contribution to sensitivity and resistance to immune checkpoint inhibitors (ICI), we hypothesized that guadecitabine (hypomethylating agent) and atezolizumab (anti-PD-L1) together would potentiate a clinical response in patients with metastatic urothelial carcinoma (UC) unresponsive to initial immune checkpoint blockade therapy. Patients and Methods:We designed a single arm Phase II study (NCT03179943) with a safety run-in to identify the recommended phase II dose of the combination therapy of guadecitabine and atezolizumab. Patients with recurrent/advanced urothelial carcinoma who had previously progressed on ICI therapy with PD-1 or PD-L1 targeting agents were eligible. Pre-planned correlative analysis was performed to characterize peripheral immune dynamics and global DNA methylation, transcriptome, and immune infiltration dynamics of patient tumors. Results: Safety run-in enrolled 6 patients and Phase II enrolled 15 patients before the trial was closed for futility. No dose-limiting toxicity was observed. Four patients, with best response of stable disease, exhibited extended tumor control (8-11 months) and survival (>14 months). Correlative analysis revealed lack of DNA demethylation in tumors after 2 cycles of treatment. Increased peripheral immune activation and immune infiltration in tumors after treatment correlated with progression-free survival and stable disease. Furthermore, high IL-6 and IL-8 levels in the patients’ plasma associates with short survival. Conclusions: No RECIST responses were observed after combination therapy in this trial. Although we could not detect the anticipated tumor-intrinsic effects of guadecitabine, the addition of hypomethylating agent to ICI therapy induced immune activation in a few patients, which associated with longer patient survival.
Year:
2024
Supplementary Tables Supplementary Table 1: Patient and tumor sample information Supplementary Table 2: Tumor mutation burden Supplementary Table 3: Unfiltered whole exome sequencing mutation analysis Supplementary Table 4: Filtered whole exome sequencing mutation analysis Supplementary Table 5: Immunohistochemistry scores of tumors Supplementary Table 6: FACS panel for PBMC analysis Supplementary Table 7: Geometric mean fluorescence intensity (GMFI) from PBMC FACS Supplementary Table 8: Representativeness of Study Participants
Year:
2024
Supplementary Tables Supplementary Table 1: Patient and tumor sample information Supplementary Table 2: Tumor mutation burden Supplementary Table 3: Unfiltered whole exome sequencing mutation analysis Supplementary Table 4: Filtered whole exome sequencing mutation analysis Supplementary Table 5: Immunohistochemistry scores of tumors Supplementary Table 6: FACS panel for PBMC analysis Supplementary Table 7: Geometric mean fluorescence intensity (GMFI) from PBMC FACS Supplementary Table 8: Representativeness of Study Participants
Year:
2024
Collaborators (11)
Sandip Patel
Associate Professor
Moores Cancer Center, UC San Diego Health
Kerry S Campbell
Professor
Fox Chase Cancer Center
Justin Kulchycki
Van Andel Institute
WOONBOK CHUNG
Assistant Professor
Coriell Institute For Medical Research
Ezra Cohen
Professor of Medicine
Moores Cancer Center, UC San Diego Health
Hui Shen
Van Andel Institute
Jozef Madzo
Director
The Wistar Institute
Jean-Pierre J Issa
Coriell Institute For Medical Research
Hyo Sik Jang
Assistant Professor
Van Andel Institute
Alexander MacFarlane IV
Assistant Research Professor
Temple University
Eric Ross
Research Professor
Fox Chase Cancer Center
Make your next move.
Prepare your application
Review drafts before you send them.